Inactive Instrument

Skyline Medical Inc Stock Nasdaq

Equities

US83084T6064

Medical Equipment, Supplies & Distribution

Sales 2022 1.51M Sales 2023 1.78M Capitalization 13.37M
Net income 2022 -25M Net income 2023 -14M EV / Sales 2022 1.5 x
Net cash position 2022 21.89M Net cash position 2023 5.87M EV / Sales 2023 4.21 x
P/E ratio 2022
-0.87 x
P/E ratio 2023
-0.94 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 96.45%
More Fundamentals * Assessed data
Dynamic Chart
FUJIFILM Wako Chemicals U.S.A. Corporation and Predictive Oncology Announce Collaboration to Reduce Protein Interference in Bacterial Endotoxin Detection Testing of Biopharmaceuticals CI
Transcript : Predictive Oncology Inc., Q4 2023 Earnings Call, Apr 01, 2024
Predictive Oncology Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Predictive Oncology Inc. Announces Resignation of Pamela Bush, as Chief Business Officer, Effective from February 15, 2024 CI
Transcript : Predictive Oncology Inc., Q3 2023 Earnings Call, Nov 14, 2023
Earnings Flash (POAI) PREDICTIVE ONCOLOGY Posts Q3 Revenue $715,056 MT
Predictive Oncology Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Predictive Oncology Inc. Announces Chief Financial Officer Changes CI
Predictive Oncology Inc. Announces Executive Changes CI
Transcript : Predictive Oncology Inc., Q2 2023 Earnings Call, Aug 10, 2023
Earnings Flash (POAI) PREDICTIVE ONCOLOGY Posts Q2 Revenue $490,110 MT
Predictive Oncology Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2023 CI
Predictive Oncology Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Predictive Oncology Relocates Corporate Headquarters to Pittsburgh Facility MT
Predictive Oncology Inc. Appoints Andrew Einhorn to Its Business Advisory Board CI
More news
Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence (AI) to support the development of cancer therapies. The Company operates through three segments: Pittsburgh, Birmingham, and Eagan. Pittsburgh segment provides services, which include the application of artificial intelligence (AI) using its proprietary biobank of 150,000 plus tumor samples. Pittsburgh segment also develops tumor-specific in vitro models for oncology drug discovery and research. Birmingham segment focuses on contract services and research for biopharmaceutical company clients and academic collaborators, focused on solubility improvements, stability studies, and protein production. Specifically, Birmingham provides optimized formulations for vaccines, antibodies, and other protein therapeutics. Eagan segment produces the STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal.
More about the company